<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>AYTU</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<h1 id="aytu-biopharma-inc.">Aytu BioPharma, Inc.</h1>
<h2 id="business-summary">Business summary</h2>
<ul>
<li>Commercial-stage pharmaceutical company focused on CNS diseases;
cornerstone asset is EXXUA (gepirone ER) for major depressive disorder
(MDD) in adults.</li>
<li>Current portfolio includes ADHD products Adzenys XR-ODT
(amphetamine) and Cotempla XR-ODT (methylphenidate), plus pediatric
brands Karbinal ER and Poly‑Vi‑Flor/Tri‑Vi‑Flor.</li>
<li>U.S.-focused commercialization with ~45 sales territories and the
Aytu RxConnect patient access platform; international out-licensing in
Israel (Medomie) and Canada (Lupin).</li>
<li>R&amp;D largely suspended to prioritize cash flow and growth in
commercial brands; operates as a single reportable segment.</li>
<li>Manufacturing transitioned to U.S.-based CMO for ADHD products;
other products supplied via third-party partners.</li>
</ul>
<h2 id="recent-developments">Recent developments</h2>
<ul>
<li>Signed exclusive U.S. commercialization agreement (June 2025) for
EXXUA; launch targeted for Q4 calendar 2025; upfront $3.0m paid with
additional milestone/royalty economics.</li>
<li>Completed wind down and divestiture of Consumer Health business
(July 31, 2024); presented as discontinued operations.</li>
<li>Manufacturing transfer of Adzenys and Cotempla to a U.S. CMO
completed in Q4 FY2024 to improve margins.</li>
<li>Financing and capital structure: raised $16.6m gross ($14.8m net)
equity (June 2025); amended Eclipse facility (Term Loan $13.0m; expanded
revolver and incremental advance).</li>
<li>Patent litigation: received Paragraph IV for Adzenys (Granules);
infringement suit filed Dec 2024 with trial set for Dec 7, 2026; prior
settlements allow potential generic entry—Adzenys (Sept 1, 2025),
Cotempla (July 1, 2026).</li>
<li>Subsequent event: transferred all AR101 (enzastaurin) rights to
EnzCo (Aug 5, 2025), terminating prior related obligations.</li>
<li>Monitoring new U.S. tax law (OBBBA, July 2025) for potential
impacts; no material cybersecurity incidents reported in FY2025.</li>
</ul>
<h2 id="key-issues">Key issues</h2>
<ul>
<li>Path to profitability and liquidity: continued net losses and modest
operating cash burn; reliance on debt facilities and capital
markets.</li>
<li>Generic risk to ADHD franchise: settlement dates and active
litigation could pressure revenue/margins; Adzenys potential generic
entry as early as Sept 2025.</li>
<li>Payer/pricing and controlled-substance constraints: DEA quotas,
reimbursement dynamics, and policy changes could impact volumes and
access.</li>
<li>Customer concentration: four customers represented 85% of FY2025
gross revenue and 89% of A/R.</li>
<li>Supply chain and third-party manufacturing dependence;
inflation/tariffs may affect costs; need to secure stable API and
finished product supply.</li>
</ul>
<h2 id="fy-financial-summary-usd">FY financial summary (USD)</h2>
<table>
<colgroup>
<col style="width: 76%" />
<col style="width: 11%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr>
<th>Metric (USD ‘000s)</th>
<th>FY 2025</th>
<th>FY 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue (Net)</strong></td>
<td>66,382</td>
<td>65,183</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>45,831</td>
<td>49,054</td>
</tr>
<tr>
<td>Gross Margin %</td>
<td>69%</td>
<td>75%</td>
</tr>
<tr>
<td><strong>Operating Income (Loss)</strong></td>
<td>(7,827)</td>
<td>(1,591)</td>
</tr>
<tr>
<td>EBITDA (Operating income + D&amp;A)</td>
<td>(2,450)</td>
<td>5,134</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Net Income (Loss)</strong></td>
<td>(13,562)</td>
<td>(15,844)</td>
</tr>
<tr>
<td>Net Income (Loss) from Continuing Operations</td>
<td>(14,182)</td>
<td>(12,520)</td>
</tr>
<tr>
<td>Cash Flow from Operations</td>
<td>(1,937)</td>
<td>(1,388)</td>
</tr>
<tr>
<td>Capital Expenditures (cash purchases of PP&amp;E)</td>
<td>(228)</td>
<td>(329)</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>(3,703)</td>
<td>(5,059)</td>
</tr>
<tr>
<td>Income Tax Expense (Continuing Ops)</td>
<td>(437)</td>
<td>(2,142)</td>
</tr>
<tr>
<td>ADHD Portfolio Revenue</td>
<td>57,576</td>
<td>57,784</td>
</tr>
<tr>
<td>Pediatric Portfolio Revenue</td>
<td>8,769</td>
<td>7,280</td>
</tr>
<tr>
<td>Cash &amp; Cash Equivalents (period-end)</td>
<td>30,952</td>
<td>20,006</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>EBITDA shown is a simple calculation: Operating income (loss) +
Depreciation, Amortization &amp; Accretion (per cash flow statement:
$5,377 in FY2025; $6,725 in FY2024). Adjusted EBITDA was not
disclosed.</li>
<li>Net income (loss) includes discontinued operations; Consumer Health
was divested and presented as discontinued operations in FY2025.</li>
<li>Capital expenditures represent cash outflows for fixed asset
purchases (negative values).</li>
</ul>
<h2 id="capitalization-cash-debt-and-enterprise-value">Capitalization,
Cash, Debt, and Enterprise Value</h2>
<p>Assumptions and sources (if applicable):</p>
<ul>
<li>Stock price provided by user: $1.925</li>
<li>Basic shares outstanding: 9,911,913 (as of September 15, 2025, per
10-K)</li>
<li>Fully diluted includes in-the-money (ITM) securities:
<ul>
<li>Prefunded warrants outstanding at 6/30/25: 10,293,983; 935,000
exercised post-quarter (July–Sept 2025) → 9,358,983 remaining ITM
(exercise price $0.0001)</li>
<li>Tranche A warrants: 2,173,912 at $1.59 (ITM at $1.925)</li>
<li>Unvested restricted stock: 32,916</li>
<li>Options (WAEP ~$4.51) and other OTM warrants excluded</li>
</ul></li>
<li>Cash and debt from FY2025 10-K (as of June 30, 2025): Cash $30.952m;
Debt $22.063m (Term Loan $13.0m + Revolver $9.063m)</li>
<li>Pro forma cash adjustment: $3.1m paid to Tris in Q1 FY2026
(settlement under fixed payment arrangements; reduces cash, not
debt)</li>
<li>Prefunded warrant exercises bring de minimis cash ($0.0001 per
share)</li>
</ul>
<table>
<colgroup>
<col style="width: 44%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price</td>
<td>$1.925</td>
</tr>
<tr>
<td>Basic Shares</td>
<td>9,911,913</td>
</tr>
<tr>
<td>ITM Prefunded Warrants (remaining post exercises)</td>
<td>9,358,983</td>
</tr>
<tr>
<td>ITM Tranche A Warrants ($1.59)</td>
<td>2,173,912</td>
</tr>
<tr>
<td>Unvested Restricted Stock</td>
<td>32,916</td>
</tr>
<tr>
<td>Fully Diluted Shares (sum of above)</td>
<td>21,477,724</td>
</tr>
<tr>
<td>Implied Market Cap (Basic)</td>
<td>$19.08m</td>
</tr>
<tr>
<td>Implied Market Cap (Fully Diluted)</td>
<td>$41.35m</td>
</tr>
<tr>
<td>Minus: Cash (6/30/25)</td>
<td>$30.95m</td>
</tr>
<tr>
<td>Add: Debt (6/30/25)</td>
<td>$22.06m</td>
</tr>
<tr>
<td>EV (Basic)</td>
<td>$10.19m</td>
</tr>
<tr>
<td>EV (Fully Diluted)</td>
<td>$32.46m</td>
</tr>
<tr>
<td>Pro forma Cash (after $3.1m Tris payment)</td>
<td>$27.85m</td>
</tr>
<tr>
<td>Pro forma EV (Basic)</td>
<td>$13.29m</td>
</tr>
<tr>
<td>Pro forma EV (Fully Diluted)</td>
<td>$35.56m</td>
</tr>
<tr>
<td>Notes</td>
<td>Debt includes Term Loan ($13.0m) + Revolver ($9.063m). An
incremental advance under the revolver began amortizing at $125k/month
from Aug 1, 2025 (small effect not reflected).</td>
</tr>
</tbody>
</table>
<h2 id="valuation">Valuation</h2>
<p>Assumptions and sources:</p>
<ul>
<li>FY2025 EBITDA = Operating income (loss) + D&amp;A&amp;A = (-$7.827m)
+ $5.377m = -$2.450m</li>
<li>EV from table above</li>
</ul>
<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2025 EBITDA</td>
<td>$(2.45)m</td>
</tr>
<tr>
<td>EV (Basic)</td>
<td>$10.19m</td>
</tr>
<tr>
<td>EV (Fully Diluted)</td>
<td>$32.46m</td>
</tr>
<tr>
<td>EV/EBITDA (Basic)</td>
<td>NM (negative EBITDA)</td>
</tr>
<tr>
<td>EV/EBITDA (Fully Diluted)</td>
<td>NM (negative EBITDA)</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>With negative EBITDA in FY2025, EV/EBITDA is not meaningful. For
context only, EV/Revenue ≈ 0.15x (basic) and 0.49x (fully diluted) using
FY2025 revenue of $66.4m.</li>
</ul>
</body>
</html>
